Waters Introduces Next-Generation Microflow LC Columns with MaxPeak Premier Technology, Delivering Higher Sensitivity with Lower Sample and Solvent Usage
MWN-AI** Summary
Waters Corporation has unveiled its next-generation 1 mm I.D. microflow liquid chromatography (LC) columns featuring its innovative MaxPeak™ Premier Technology, a significant advancement aimed at enhancing sensitivity while reducing sample and solvent consumption. This breakthrough product is tailored for high-throughput bioseparations across various applications, including drug metabolism and pharmacokinetics (DMPK), as well as 'omics studies. The new columns offer up to twice the sensitivity compared to conventional stainless steel microflow columns, which translates to improved detection and quantitation limits.
One of the standout features of these microflow columns is their ability to utilize up to 75% less sample than traditional 2.1 mm I.D. columns, making them particularly valuable for high-stakes fields such as personalized medicine and gene therapy where material availability is often limited. Additionally, they help laboratories decrease solvent usage by as much as four times, aiding in sustainability initiatives and lowering operational costs without sacrificing performance.
Waters’ MaxPeak High Performance Surface (HPS) Technology minimizes nonspecific adsorption and enhances analyte recovery, which is crucial for research involving challenging substances like phosphorylated peptides. The columns deliver sharper peaks and improved reproducibility from the very beginning of analysis, pushing the limits of current separation technologies.
As emphasized by Rob Carpio, Senior Vice President at Waters, this launch reflects the company's commitment to overcoming barriers for labs engaged in pharmaceutical and biopharmaceutical development. The new microflow LC columns will be globally available starting February 17, 2026, marking a significant milestone in analytical chemistry innovation and enhancing the efficiency and accuracy of laboratory workflows.
MWN-AI** Analysis
Waters Corporation's recent launch of its next-generation 1 mm I.D. microflow LC columns integrated with MaxPeak Premier Technology marks a significant advancement in analytical chromatography, particularly for sectors such as biopharmaceuticals and ‘omics research. This innovation delivers up to twice the sensitivity of traditional stainless steel microflow columns and reduces sample usage by up to 75%, all while significantly cutting solvent consumption by as much as 75%.
From an investment perspective, the introduction of these columns positions Waters as an industry leader in high-performance chromatography. The enhanced analytical capabilities will likely attract high-throughput laboratories engaged in pharmaceutical discovery, aiding them in tackling the critical challenges during the development of life-saving treatments. As demands for greener laboratory practices increase, Waters’ reduced solvent consumption aligns well with sustainability goals—providing potential cost savings and operational efficiencies.
Looking forward, investors should consider the long-term implications of this technological innovation. The ability to provide more accurate data while conserving precious resources positions Waters favorably in a highly competitive market. Moreover, as the global emphasis on personalized medicine and cancer therapies grows, the demand for sensitive and efficient analytical tools will heighten.
The stock's performance will depend on the adoption rate of these new microflow columns in laboratories worldwide. A successful marketing strategy and customer engagement will be crucial. Waters should also focus on securing partnerships with biotech companies and research institutions to expand the reach of this technology.
In conclusion, investors may want to position themselves in Waters Corporation, given its potential for revenue growth and leadership role in advancing chromatography technology. The synergistic benefits of improved performance with lower resource consumption could result in sustained competitive advantages, appealing to both environmentally-conscious investors and those seeking innovation-driven growth.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
Headlines:
- Delivers up to 2× higher sensitivity than stainless steel microflow columns, lowering detection and quantitation limits across high-throughput bioseparations, DMPK, and 'omics applications.1
- Uses up to 75% less sample than 2.1 mm I.D. columns, conserving precious materials such as cell and gene therapy and personalized medicine candidates while delivering deeper insights. 2
- Reduces solvent consumption by up to 4× versus 2.1 mm I.D. columns, helping laboratories meet sustainability goals, lower operating costs, and accelerate time to results without compromising performance. 2
MILFORD, Mass., Feb. 17, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) today launched 1 mm I.D. liquid chromatography (LC) columns with Waters' MaxPeak™ Premier Technology for its ACQUITY™, BioResolve™, and GTxResolve™ Column brands. Significantly improving sensitivity while minimizing solvent and sample waste, the new microflow columns deliver high-quality results across bioanalysis, pharmaceutical discovery and development, and metabolomics, proteomics and lipidomics – all areas where both sample availability and time are limited.
This launch builds on the Company's strong cadence of high-impact chemistry innovation, redefining what is possible in the separation of larger, more complex molecules by exceeding the limits of current technologies.
"Waters continues to invest in the advancement of breakthrough technologies to remove common obstacles for our customers in high-throughput pharmaceutical and biopharmaceutical laboratories, accelerating and simplifying the development of life-changing therapies," said Rob Carpio, Senior Vice President, Waters Analytical Sciences, Waters Corporation. "We know that in disciplines such as cell and gene therapy and personalized cancer medicines, sample availability is limited and analyte recovery is critical. Today, we are proud to introduce our new microflow LC columns with MaxPeak Premier Technology that protect these precious assets, while raising the bar on sensitivity, data quality, and reproducibility."
The new microflow LC columns apply Waters' MaxPeak High Performance Surface (HPS) Technology to a 1 mm I.D. format. This significant advancement minimizes nonspecific adsorption (NSA) and improves recovery for small molecules, peptides, and oligonucleotides. MaxPeak HPS Technology is of particular benefit for those investigating molecules with challenging analyte recovery, such as phosphorylated peptides, by removing analytical barriers and speeding workflows.
"We saw a strong benefit matching, or even exceeding, our analytical sensitivity requirements when switching from 2.1 mm I.D. stainless steel columns to Waters' MaxPeak Premier Technology columns. It's great to have MaxPeak Technology now available in 1 mm I.D. microflow columns. They'll give our metabolomics team the opportunity to save solvent while delivering reproducible, fast, and highly accurate results in high-throughput operations," said Oliver Fiehn, Ph.D., Professor, University of California, Davis.
Using these columns, scientists can consistently expect sharper peaks, enhanced peak capacity, and reduced peak tailing even at low flow rates, along with highly reproducible performance from the very first injection. These benefits significantly reduce the time and variability associated with column passivation in traditional stainless steel column designs. For customers transitioning from 2.1 mm I.D. analytical-scale LC columns to microflow formats, the new 1 mm I.D. columns deliver equivalent or improved sensitivity, while using only one-quarter of the solvent and sample required for analytical flow, helping labs meet their environmental goals while improving analytical performance.
The new 1 mm I.D. columns with Waters' MaxPeak Premier Technology will be available globally beginning February 17, 2026, with immediate shipment.
Additional Resources: Microflow Columns with MaxPeak Premier Technology
Waters, MaxPeak, ACQUITY, BioResolve and GTxResolve are trademarks of Waters Corporation or its affiliates.
ABOUT: Waters Corporation (NYSE: WAT) is a global leader in life sciences and diagnostics, dedicated to accelerating the benefits of pioneering science through analytical technologies, informatics, and service. With a focus on regulated, high-volume testing environments, our innovative portfolio harnesses deep scientific expertise across chemistry, physics, and biology. We collaborate with customers around the world to advance the release of effective, high-quality medicines, ensure the safety of food and water, and drive better patient outcomes by detecting diseases earlier, managing routine infections, and combating antibiotic resistance. Through a shared culture of relentless innovation, our passionate team of ~16,000 colleagues turn scientific challenges into breakthroughs that improve lives worldwide. For more information, please visit www.waters.com/about.
References:
1. Application note: "Enhanced Recovery and Peak Shape of Acidic Peptides with BioResolve™ 1 mm I.D. Columns with MaxPeak™ Premier Technology"
2. Application note: "Improving Sensitivity and Analytical Method Greenness using MaxPeak™ Premier 1.0 mm I.D. Columns"
Contact:?
Molly Gluck
Head of External Communications
Waters Corporation?
508.498.9732
molly_gluck@waters.com?
SOURCE Waters Corporation
FAQ**
How does Waters Corporation WAT plan to leverage the higher sensitivity of the new microflow LC columns with MaxPeak Premier Technology to enhance its position in the biopharmaceutical industry?
In what ways can the reduced solvent and sample usage of Waters Corporation WAT’s new microflow LC columns impact laboratory operational costs and sustainability goals for clients?
What specific advantages does Waters Corporation WAT's MaxPeak Premier Technology provide in terms of nonspecific adsorption reduction and analyte recovery for challenging molecules?
How does the introduction of Waters Corporation WAT's 1 mm I.D. columns compare to existing solutions, and what potential market applications are being targeted with this innovative technology?
**MWN-AI FAQ is based on asking OpenAI questions about Waters Corporation (NYSE: WAT).
NASDAQ: WAT
WAT Trading
-4.11% G/L:
$306.18 Last:
458,185 Volume:
$311.65 Open:
